TSPT Dividend History & Description — Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. Co.'s approved product, Intermezzo (zolpidem tartrate) sublingual tablet, is a sublingual formulation of zolpidem approved for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Co. has a license to commercialize Shin Nippon Biomedical Laboratories Ltd.'s (SNBL) proprietary nasal drug delivery technology to develop TO-2070. Co. is developing TO-2070 as a treatment for acute migraine using SNBL's proprietary nasal powder drug delivery system. When considering the Paratek Pharmaceuticals Inc stock dividend history, we have taken known splits into account, such that the TSPT dividend history is presented on a split-adjusted ("apples to apples") basis. Paratek Pharmaceuticals Inc dividend history is presented both in graphical/chart form, and as a TSPT dividend history data table along the right-hand column.